吡柔比星联合顺铂膀胱灌注化疗对早期膀胱癌VEGF和HER-2表达的影响

Effects of pirarubicin combined with cisplatin bladder perfusion chemotherapy on the expressions of VEGF and HER-2 in patients with early bladder cancer

目的探讨吡柔比星联合顺铂膀胱灌注化疗对早期膀胱癌血管内皮生长因子(VEGF)、人类表皮生长因子受体-2(HER-2)表达的影响。方法收治的早期膀胱癌患者80例,参照抽签法分为对照组和试验组,每组40例。2组患者均于术后进行化疗,对照组给予顺铂常规化疗,研究组基于对照组联合吡柔比星行膀胱灌注化疗,比较2组患者治疗后VEGF水平、HER-2表达情况,生活质量变化,临床疗效,复发率及生存率,毒副反应。结果治疗后,试验组VEGF低于对照组,比较差异有统计学意义(P<0.05);试验组HER-2低表达率、过表达率优于对照组,差异有统计学意义(P<0.05);试验组生活质量优于对照组(P<0.05);试验组客观缓解率为87.50%高于对照组的62.50%,差异有统计学意义(P<0.05);试验组复发率、生存率优于对照组(P<0.05);2组毒副反应比较差异无统计学意义(P>0.05)。结论吡柔比星联合顺铂膀胱灌注化疗能够显著改善早期膀胱癌患者VEGF水平,调节HER-2表达,提高患者的生活质量。

Objective To investigate the effects of pirarubicin combined with cisplatin bladder perfusion chemotherapy on the expressions of vascular endothelial growth factor （VEGF） and human epidermal growth factor receptor （ HER-2 ） in patients with early bladder cancer. Methods Eighty patients with early bladder cancer who were treated in our hospital were divided into control group （ n = 40） and trial group （ n = 40 ） by means of lot method. The patients in both groups were treated by chemotherapy after surgery, the patients in control group were treated by routine chemotherapy with cisplatin, however, the patients in trial group, on the basis of control group, were treated by pirarubicin bladder perfusion chemotherapy. After treatment the changes of expression levels of VEGF and HER-2, life quality, clinical curative effects, relapse rate, survival rate, adverse reaction were observed and compared between two groups. Results After treatment, the expression levels of VEGF in trial group were significantly lower than those in control group [ （ 52.30 ± 3.41 ） ng/L vs （56. 844 ± 4.37 ） ng/L, P 〈 0.05 ]. Moreover the low expression rate and overexpression rate of HER-2 in trial group were superior to those in control group （ P 〈 0.05 ）. The patient＇ s life quality in trial group was superior to that in control group （ P 〈 0.05 ）. The objective remission rate in trial group was 87.50% （35/40） , which was significantly higher than that [ 62.50% （25/40） ] in control group （ P 〈 0.05 ）. The relapse rate and survival rate in trial group were superior to those in control group （ P 〈 0.05 ）. Moreover there were no significant differnces in the incidence rates of adverse reaction between two groups （ P 〉 0.05 ）. Conclusion The pirarubicin combined with cisplatin bladder perfusion chemotherapy can improve obviously the expression levels of VEGF, regulate the expression of HER-2 and improve the life quality of patients with early bladder cancer.